Take a Closer Look at the Promise of Our iADC Next-Gen Technology
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Sutro’s Whitepaper, “STRO-002 from Sutro Biopharma offers hope to patients with rare, otherwise fatal pediatric tumors. Sutro Biopharma’s STRO-002 puts young leukemia patients into remission”
Six Product Candidates Advancing in the Clinic and Late-Stage Discovery Programs
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.
Best Places to Work
Sutro is honored to be named, BioSpace Best Places to Work for 2023. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done!
To read the report, click the link .
Diversity, Equity, Inclusion and Belonging (DEIB)
Our Commitment to Change.
Sutro Biopharma has partnered with California Life Sciences Association (CLSA) to create a more diverse industry to spark solutions for a better healthier world. CLSA members have raised $1M with a goal of sustaining 3-year commitments of $1M annually for Racial & Social Equity Initiative We Commit To Change